2017 Annual Meeting | N9 - Neuroscience in the Clinic: Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment
| 01:00 PM - 01:05 PM | Luncheon |
Introduction
Heather Moss, MD, PhD, FAAN |
| 01:00 PM - 03:00 PM | Abstract |
001 - Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults
Michael Ward, MD, PhD |
| 01:00 PM - 03:00 PM | Abstract |
002 - What are the phenotypes of Brazilian patients with autossomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)?: Neurological, ophthalmological and neuroimaging features of seven genetically confirmed cases.
|
| 01:05 PM - 01:10 PM | Speaker |
Case: Afferent Visual Dysfunction
|
| 01:10 PM - 01:20 PM | Speaker |
Clinical Aspects of Afferent Visual Dysfunction in Neuro-degenerative Diseases
Victoria S. Pelak, MD, FAAN |
| 01:20 PM - 01:35 PM | Speaker |
Scientific Aspects of Afferent Visual Dysfunction in Neuro-degenerative Disease
Geoffrey K. Aguirre, MD, PhD |
| 01:35 PM - 01:45 PM | Speaker |
N9.001: Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults
Michael Ward, MD, PhD |
| 01:45 PM - 01:50 PM | Speaker |
Case: Efferent Visual Dysfunction
|
| 01:50 PM - 02:00 PM | Speaker |
Clinical Aspects of Efferent Visual Dysfunction in Neuro-degenerative Diseases
Matthew J. Thurtell, MD |
| 02:00 PM - 02:15 PM | Speaker |
Eye Movement and Reading Abnormalities in Parkinsonism
Y. Joyce Liao, MD, PhD |
| 02:15 PM - 02:25 PM | Speaker |
N9.002: What are the phenotypes of Brazilian patients with autossomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)?: Neurological, ophthalmological and neuroimaging features of seven genetically confirmed cases
|
| 02:25 PM - 02:35 PM | Speaker |
The Visual System as a Biomarker for Neuro-degenerative Diseases
Gregory P. Van Stavern, MD, FAAN |
| 02:35 PM - 03:00 PM | Speaker |
Panel Discussion
|
| Bruce L. Miller, MD, FAAN | Dr. Miller has nothing to disclose. |
| Victoria S. Pelak, MD, FAAN | Dr. Pelak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Pelak has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for North American Neuro-ophthalmology Society. Dr. Pelak has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law Firms. The institution of Dr. Pelak has received research support from Biogen. Dr. Pelak has received publishing royalties from a publication relating to health care. |
| Fernando Kok, MD | No disclosure on file |
| Gregory P. Van Stavern, MD, FAAN | Dr. Van Stavern has received publishing royalties from a publication relating to health care. |
| Geoffrey K. Aguirre, MD, PhD | Dr. Aguirre has received stock or an ownership interest from Nia therapeutics. The institution of Dr. Aguirre has received research support from Lion's Foundation. The institution of Dr. Aguirre has received research support from National Institutes of Health. The institution of Dr. Aguirre has received research support from Johnson and Johnson. The institution of Dr. Aguirre has received research support from Department of Defense. |
| Y. Joyce Liao, MD, PhD | No disclosure on file |
| Ari Green, MD | Dr. Green has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pipeline Therapeutics. Dr. Green has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Green has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Green has received research support from NINDS. The institution of Dr. Green has received research support from NMSS. The institution of Dr. Green has received research support from NIA. The institution of Dr. Green has received research support from Adelson Research Foundation. Dr. Green has received intellectual property interests from a discovery or technology relating to health care. Dr. Green has received personal compensation in the range of $500-$4,999 for serving as a Study Section with NINDS. Dr. Green has a non-compensated relationship as a Author with Viela Bio that is relevant to AAN interests or activities. |
| Joel Kramer, PhD | The institution of Dr. Kramer has received research support from tau consortium. Dr. Kramer has received publishing royalties from a publication relating to health care. |
| Matthew J. Thurtell, MD | Dr. Thurtell has received publishing royalties from a publication relating to health care. |
| Heather Moss, MD, PhD, FAAN | Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Twenty Twenty Therapeutics. Dr. Moss has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Verana Health. Dr. Moss has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink Inc. Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms. The institution of Dr. Moss has received research support from NIH. The institution of Dr. Moss has received research support from Department of Defense. The institution of Dr. Moss has received research support from Research to Prevent Blindness. Dr. Moss has received intellectual property interests from a discovery or technology relating to health care. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with NASA. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with National Institutes of Health. Dr. Moss has a non-compensated relationship as a Board of Directors with North American Neuro-ophthalmology Society that is relevant to AAN interests or activities. |
| Jeffrey M. Gelfand, MD, MAS, FAAN | Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities. |
| Orlando G. Barsottini, MD, PhD | Dr. Barsottini has nothing to disclose. |
| Michael Ward, MD, PhD | No disclosure on file |
| Brianne Bettcher | No disclosure on file |
| No disclosure on file | |
| Ingrid F. De Vasconcellos, MD | No disclosure on file |
| Shubir Dutt | Mr. Dutt has nothing to disclose. |
| Jose Luiz Pedroso, MD | Dr. Pedroso has nothing to disclose. |
| Paola Giunti | No disclosure on file |